Alzamend Neuro, Inc. (ALZN) Form 10-K — Jul 22, 2026

$ALZNForm 10-KFiled Jul 22, 2026, 4:30 PM ET0001214659-26-008832Original filing

Alzamend Neuro, Inc. filed its annual report on Form 10-K, updating investors on its clinical-stage biopharmaceutical operations targeting Alzheimer’s and neuropsychiatric disorders. The company reported positive topline pharmacokinetic and pharmacodynamic data for its lead candidate AL001, demonstrating bioequivalence and superior brain penetration compared to standard lithium carbonate in healthy subjects, while also initiating a Phase II trial in bipolar disorder patients.

Key figures

Cash Position: 711000
Shares Outstanding: 4,791,525
Alzn002 trial restart date: Q1 2027
Al001 healthy subject pk peak lithium vs carbonate: 97%
Al001 healthy subject total lithium exposure vs carbonate: 101%

Price after filing

1 day: 0.0%7 days: +1.5%30 days: +23.5%

Close on the filing date to close N calendar days later (from $1.32). Historical, not a forecast.

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.